Gene copy mapping of the ERBB2/TOP2A region in breast cancer. 2004

Kris K Jacobson, and Larry E Morrison, and Benita T Henderson, and Beth A Blondin, and Kimberly A Wilber, and Mona S Legator, and Anna O'Hare, and Susan C Van Stedum, and John H Proffitt, and Steve A Seelig, and John S Coon
Vysis, Inc, Downers Grove, IL 60515, USA.

ERBB2 is one of the most important oncogenes in breast cancer, and its disordered expression is commonly associated with gene amplification. Amplification of at least one gene near ERBB2, topoisomerase IIalpha (TOP2A), has been shown to be clinically significant, but the prevailing patterns of gene amplification in this region of chromosome arm 17q have not been studied systematically in clinical cases of breast cancer. For characterizing this region, a commercial ERBB2-containing contig probe and 7 probes prepared from single overlapping BAC and P1 clones lying telomeric to ERBB2 and including TOP2A were hybridized to 77 ERBB2-amplified archival breast tumor specimens from 75 patients. The 7 single-clone probes covered a region of approximately 650 kb starting 114 kb telomeric to ERBB2. Amplification of the ERBB2 contig target alone was found in 32% of the tumors, whereas all 8 probe targets were amplified in 12% of the tumors, based on an amplification criterion of there being more than or equal to 2 targets per chromosome 17 centromere. When one of the 7 overlapping probes encompassing TOP2A indicated amplification within a specimen, all probes telomeric to that probe usually showed amplification. Only 5 specimens had regions of normal or deleted targets separating 2 amplified targets. Also, tumors that showed deletion of TOP2A usually showed deletion of one or more contiguous targets. The observed patterns of amplification and deletion are consistent with the break-fusion-bridge model for gene amplification. TOP2A was amplified in 25% of all tumor specimens and was deleted in 24%, based on a deletion criterion of there being fewer than or equal to 0.75 targets per chromosome 17 centromere. Considering the relevance of the TOP2A gene product to anthracycline therapy and the wealth of other cancer-associated genes within the ERBB2/TOP2A region, the pattern of amplification and deletion near ERBB2 and TOP2A may have a dramatic effect on the malignant potential of breast carcinomas and their response to therapy.

UI MeSH Term Description Entries
D008957 Models, Genetic Theoretical representations that simulate the behavior or activity of genetic processes or phenomena. They include the use of mathematical equations, computers, and other electronic equipment. Genetic Models,Genetic Model,Model, Genetic
D011995 Recombination, Genetic Production of new arrangements of DNA by various mechanisms such as assortment and segregation, CROSSING OVER; GENE CONVERSION; GENETIC TRANSFORMATION; GENETIC CONJUGATION; GENETIC TRANSDUCTION; or mixed infection of viruses. Genetic Recombination,Recombination,Genetic Recombinations,Recombinations,Recombinations, Genetic
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002503 Centromere The clear constricted portion of the chromosome at which the chromatids are joined and by which the chromosome is attached to the spindle during cell division. Centromeres
D002872 Chromosome Deletion Actual loss of portion of a chromosome. Monosomy, Partial,Partial Monosomy,Deletion, Chromosome,Deletions, Chromosome,Monosomies, Partial,Partial Monosomies
D002874 Chromosome Mapping Any method used for determining the location of and relative distances between genes on a chromosome. Gene Mapping,Linkage Mapping,Genome Mapping,Chromosome Mappings,Gene Mappings,Genome Mappings,Linkage Mappings,Mapping, Chromosome,Mapping, Gene,Mapping, Genome,Mapping, Linkage,Mappings, Chromosome,Mappings, Gene,Mappings, Genome,Mappings, Linkage
D002886 Chromosomes, Human, Pair 17 A specific pair of GROUP E CHROMOSOMES of the human chromosome classification. Chromosome 17
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA

Related Publications

Kris K Jacobson, and Larry E Morrison, and Benita T Henderson, and Beth A Blondin, and Kimberly A Wilber, and Mona S Legator, and Anna O'Hare, and Susan C Van Stedum, and John H Proffitt, and Steve A Seelig, and John S Coon
May 2014, Journal of clinical pathology,
Kris K Jacobson, and Larry E Morrison, and Benita T Henderson, and Beth A Blondin, and Kimberly A Wilber, and Mona S Legator, and Anna O'Hare, and Susan C Van Stedum, and John H Proffitt, and Steve A Seelig, and John S Coon
April 2010, Molecular oncology,
Kris K Jacobson, and Larry E Morrison, and Benita T Henderson, and Beth A Blondin, and Kimberly A Wilber, and Mona S Legator, and Anna O'Hare, and Susan C Van Stedum, and John H Proffitt, and Steve A Seelig, and John S Coon
January 2006, Neoplasma,
Kris K Jacobson, and Larry E Morrison, and Benita T Henderson, and Beth A Blondin, and Kimberly A Wilber, and Mona S Legator, and Anna O'Hare, and Susan C Van Stedum, and John H Proffitt, and Steve A Seelig, and John S Coon
January 2009, Breast cancer research : BCR,
Kris K Jacobson, and Larry E Morrison, and Benita T Henderson, and Beth A Blondin, and Kimberly A Wilber, and Mona S Legator, and Anna O'Hare, and Susan C Van Stedum, and John H Proffitt, and Steve A Seelig, and John S Coon
January 2008, Acta oncologica (Stockholm, Sweden),
Kris K Jacobson, and Larry E Morrison, and Benita T Henderson, and Beth A Blondin, and Kimberly A Wilber, and Mona S Legator, and Anna O'Hare, and Susan C Van Stedum, and John H Proffitt, and Steve A Seelig, and John S Coon
January 2018, EXCLI journal,
Kris K Jacobson, and Larry E Morrison, and Benita T Henderson, and Beth A Blondin, and Kimberly A Wilber, and Mona S Legator, and Anna O'Hare, and Susan C Van Stedum, and John H Proffitt, and Steve A Seelig, and John S Coon
January 2002, The American journal of pathology,
Kris K Jacobson, and Larry E Morrison, and Benita T Henderson, and Beth A Blondin, and Kimberly A Wilber, and Mona S Legator, and Anna O'Hare, and Susan C Van Stedum, and John H Proffitt, and Steve A Seelig, and John S Coon
January 1992, Journal of cancer research and clinical oncology,
Kris K Jacobson, and Larry E Morrison, and Benita T Henderson, and Beth A Blondin, and Kimberly A Wilber, and Mona S Legator, and Anna O'Hare, and Susan C Van Stedum, and John H Proffitt, and Steve A Seelig, and John S Coon
May 2011, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Kris K Jacobson, and Larry E Morrison, and Benita T Henderson, and Beth A Blondin, and Kimberly A Wilber, and Mona S Legator, and Anna O'Hare, and Susan C Van Stedum, and John H Proffitt, and Steve A Seelig, and John S Coon
March 2019, Oncology letters,
Copied contents to your clipboard!